Precision BioSciences, Inc. Common Stock
DTILPrecision BioSciences, Inc. (DTIL) is a biotechnology company focused on developing gene editing technologies to create innovative therapies for various genetic diseases and cancers. Founded on the proprietary ARCUS genome editing platform, the company aims to deliver precise and durable genetic modifications to improve patient outcomes.
Company News
The global genome editing market is projected to grow from $9.39 billion in 2025 to $23.66 billion by 2031, driven by increased funding, CRISPR advancements, and AI integration. However, off-target effects and regulatory hurdles pose significant challenges. Key developments include AI-enhanced editing systems achieving 95% reduction in off-target...
The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.
The global genetic engineering market is expected to grow from USD 1.35 billion in 2023 to USD 8.95 billion by 2033, driven by the increasing demand for biopharmaceutical products made through genetically altered processes. However, the high cost of R&D is a restraint on market growth.
The gene editing therapeutics market is expected to grow significantly, reaching $1 billion by 2029 with a CAGR of 147%. Key drivers include the increasing prevalence of chronic and rare genetic diseases, as well as the need for precision medicine.
The mean of analysts' price targets for Precision BioSciences (DTIL) points to a 200.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
